[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Quest Diagnostics Inc (DGX)

Quest Diagnostics Inc (DGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 23,048,012
  • Shares Outstanding, K 110,696
  • Annual Sales, $ 11,035 M
  • Annual Income, $ 992,000 K
  • EBIT $ 1,761 M
  • EBITDA $ 2,331 M
  • 60-Month Beta 0.58
  • Price/Sales 2.13
  • Price/Cash Flow 14.00
  • Price/Book 3.07

Options Overview Details

View History
  • Implied Volatility 28.32% (+0.58%)
  • Historical Volatility 22.13%
  • IV Percentile 90%
  • IV Rank 79.09%
  • IV High 31.28% on 04/20/26
  • IV Low 17.11% on 08/15/25
  • Expected Move (DTE 7) 4.82 (2.32%)
  • Put/Call Vol Ratio 0.18
  • Today's Volume 266
  • Volume Avg (30-Day) 748
  • Put/Call OI Ratio 0.69
  • Today's Open Interest 9,249
  • Open Int (30-Day) 9,426
  • Expected Range 203.23 to 212.87

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $2.81
  • Number of Estimates 9
  • High Estimate $2.89
  • Low Estimate $2.75
  • Prior Year $2.62
  • Growth Rate Est. (year over year) +7.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
192.83 +7.89%
on 06/18/26
219.20 -5.09%
on 07/07/26
+3.52 (+1.72%)
since 06/09/26
3-Month
186.23 +11.72%
on 05/08/26
219.20 -5.09%
on 07/07/26
+10.23 (+5.17%)
since 04/09/26
52-Week
164.65 +26.36%
on 07/15/25
219.20 -5.09%
on 07/07/26
+34.43 (+19.83%)
since 07/09/25

Most Recent Stories

More News
Quest Diagnostics Now the Largest Clinical Reference Lab to Extend Oncology Test Access Through OncoEMR MPI

American Oncology Network (AON) and other community oncology providers launching now as part of a pilot program that provides access to Haystack MRD

DGX : 208.05 (-0.08%)
Digi Power X Provides Operations and Financial Update

MIAMI, FL / ACCESS Newswire / July 7, 2026 / Digi Power X Inc. (NASDAQ:DGXX)(Cboe Canada:DGX) (the "Company" and "Digi Power X"), an AI data center infrastructure operator, today provided an update on...

DGX : 208.05 (-0.08%)
DGX.NE : 6.6800 (+6.28%)
DGX.VN : 3.790 (+5.28%)
DGXX : 4.68 (+5.41%)
Quest Diagnostics's Q2 2026 Earnings: What to Expect

Quest Diagnostics is expected to unveil its second-quarter results later this month, and analysts expect a single-digit growth in earnings.

ABT : 94.40 (-0.82%)
XLV : 162.17 (-0.08%)
DGX : 208.05 (-0.08%)
$SPX : 7,543.64 (+0.81%)
Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing

Achieving the rigorous laboratory standard broadens access for providers and patients in New York; applies to use of Haystack MRD for patients with solid tumor cancers

DGX : 208.05 (-0.08%)
Is Quest Diagnostics Stock Underperforming the S&P 500?

While Quest Diagnostics has lagged behind the S&P 500 Index over the past year, analysts are moderately optimistic about the stock’s prospects.

DGX : 208.05 (-0.08%)
$SPX : 7,543.64 (+0.81%)
TMO : 524.71 (+2.86%)
Is Labcorp Holdings Stock Underperforming the Nasdaq?

Labcorp Holdings has underperformed the Nasdaq over the past year, but analysts are highly optimistic about the stock’s prospects.

$NASX : 26,206.89 (+1.30%)
DGX : 208.05 (-0.08%)
LH : 277.63 (-0.04%)
UTI-causing Bacteria Resistant to Current Drugs, Finds National Study by Hackensack Meridian CDI and Quest Diagnostics

Published in Nature Communications , the new study finds that nearly 70% of a common bacterial strain that causes urinary tract infections, pneumonia and wound infections was non-susceptible to...

DGX : 208.05 (-0.08%)
Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026

SECAUCUS, N.J. , June 17, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report its second quarter 2026...

DGX : 208.05 (-0.08%)
Quest Diagnostics Unveils Achievements in Healthcare Access, Employee Engagement and Environmental Sustainability in 2025 Corporate Responsibility Report

SECAUCUS, N.J. , June 16, 2026 /PRNewswire/ -- Quest Diagnostics  (NYSE: DGX), a leader in diagnostic information services, today unveiled its 2025 Corporate Responsibility Report .

DGX : 208.05 (-0.08%)
Digi Power X Secures NVIDIA Vera Rubin Systems, Advancing its AI Infrastructure and Strengthening the NeoCloudz Platform

MIAMI, FL / ACCESS Newswire / June 3, 2026 / Digi Power X Inc. (Nasdaq:DGXX)(Cboe Canada:DGX) (the "Company" and "Digi Power X"), an AI data center infrastructure operator, today announced a $35 million...

DGX : 208.05 (-0.08%)
DGX.NE : 6.6800 (+6.28%)
DGX.VN : 3.790 (+5.28%)
DGXX : 4.68 (+5.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Quest Diagnostics, Inc. is the provider of commercial laboratory services. Quest provides lab testing services to physicians, hospitals, managed care organizations, employers, government institutions and other clinical laboratories. The company consists of 2 business groups - Diagnostic Information Services...

See More

Key Turning Points

3rd Resistance Point 213.91
2nd Resistance Point 212.06
1st Resistance Point 210.05
Last Price 208.05
1st Support Level 206.19
2nd Support Level 204.34
3rd Support Level 202.33

See More

52-Week High 219.20
Last Price 208.05
Fibonacci 61.8% 198.36
Fibonacci 50% 191.92
Fibonacci 38.2% 185.49
52-Week Low 164.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.